Talazoparib + Avelumab

Phase 2Monoclonal antibody

CCentre Francois Baclesse

Talazoparib + Avelumab is one of 45 small molecule programs targeting Urothelial Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urothelial CarcinomaActive, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Urothelial Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

26 2

Gemzar

Johnson & Johnson

Phase 3

24 3

Tecentriq

Roche

Phase 3

18 4

Opdivo

Bristol-Myers Squibb

Phase 3

12 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

18 6

Taxol

Teva

Phase 3

4 7

Beyfortus

BeiGene

Phase 3

3 8

Paraplatin

AAvyxa

Phase 3

10 9

Folvite

Eli Lilly

Phase 3

1 10

Vectibix

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urothelial Carcinoma1 trial

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

Recruiting·CCentre Francois Baclesse·Phase 2·NCT04678362·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Talazoparib + Avelumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Talazoparib + Avelumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Talazoparib + Avelumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Francois Baclesse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: CCentre Francois Baclesse

Talazoparib + Avelumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News